EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial

Etienne Garin, Lambros Tselikas, Boris Guiu, Julia Chalaye, Yan Rolland, Thierry de Baere, Eric Assenat, Vania Tacher, Xavier Palard, Desirée Déandreis, Denis Mariano-Goulart, Giuliana Amaddeo und 7 weitere

Journal of Nuclear Medicine · 2024-02 · 65 (2) · 264-269

DOI: 10.2967/jnumed.123.266211 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 11.01.2024. Verfasst von Etienne Garin und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute Eugene Marquis, Rennes, France; e.garin@rennes.unicancer.fr. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Venous Thrombosis. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in response and overall survival (OS) on using 90Y-loaded glass microspheres with personalized dosimetry compared with standard dosimetry in patients with nonoperable locally advanced hepatocellular carcinoma. This report sought to provide a long-term analysis of OS.

Methods

In this phase II study (ClinicalTrials.gov identifier NCT02582034), treatment was randomly assigned (1:1) with the goal to deliver either at least 205 Gy (if possible >250-300 Gy) to the index lesion in the personalized dosimetry approach (PDA) or 120 ± 20 Gy to the treated volume in the standard dosimetry approach (SDA). The 3-mo response of the index lesion was the primary endpoint, with OS being one of the secondary endpoints. This report is a post hoc long-term analysis of OS.

Results

Overall, 60 hepatocellular carcinoma patients with at least 1 lesion larger than 7 cm and more than 30% of hepatic reserve were randomized (intent-to-treat population: PDA, n = 31; SDA, n = 29), with 56 actually treated (modified intent-to-treat population: n = 28 in each arm). The median follow-up for long-term analysis was 65.8 mo (range, 2.1-73.1 mo). Median OS was 24.8 mo and 10.7 mo (hazard ratio [HR], 0.51; 95% CI, 0.29-0.9; P = 0.02) for PDA and SDA, respectively, in the modified intent-to-treat population. Median OS was 22.9 mo for patients with a tumor dose of at least 205 Gy, versus 10.3 mo for those with a tumor dose of less than 205 Gy (HR, 0.42; 95% CI, 0.22-0.81; P = 0.0095), and was 22.9 mo for patients with a perfused liver dose of 150 Gy or higher, versus 10.3 mo for those with a perfused liver dose of less than 150 Gy (HR, 0.42; 95% CI, 0.23-0.75; P = 0.0033). Lastly, median OS was not reached in patients who were secondarily resected (n = 11, 10 in the PDA group and 1 in the SDA group), versus 10.8 mo in those without secondary resection (n = 45) (HR, 0.17; 95% CI, 0.065-0.43; P = 0.0002). Only resected patients displayed favorable long-term OS rates, meaning an OS of more than 50% at 5 y.

Conclusion

After longer follow-up, personalized dosimetry sustained a meaningful improvement in OS, which was dramatically improved for patients who were accurately downstaged toward resection, including most portal vein thrombosis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsVenous ThrombosisHumansRadiometryYttrium RadioisotopesMicrospheres

Stichwörter der Autor:innen

90Y-loaded glass microspheresdownstagedhepatocellular carcinomapersonalized dosimetryportal vein thrombosis

Substanzen

Yttrium Radioisotopes

Autor:innen und Institutionen

  • Cancer Institute Eugene Marquis, Rennes, France; e.garin@rennes.unicancer.fr.
  • University of Rennes, INSERM, INRAE, Nutrition Métabolismes et Cancer U1317, Rennes, France.
  • Gustave Roussy, University of Paris-Saclay, Villejuif, France.
  • Montpellier University Hospital, Montpellier, France.
  • AP-HP, Hopitaux Universitaires Henri Mondor, Creteil, France.
  • Cancer Institute Eugene Marquis, Rennes, France.

Zitieren

APA

Garin, E., Tselikas, L., Guiu, B., Chalaye, J., Rolland, Y., de Baere, T., Assenat, E., Tacher, V., Palard, X., Déandreis, D., Mariano-Goulart, D., Amaddeo, G., Boudjema, K., Hollebecque, A., Meerun, M. A., Regnault, H., Vibert, E., Campillo-Gimenez, B., & Edeline, J. (2024). Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial. Journal of Nuclear Medicine, 65(2), 264-269. https://doi.org/10.2967/jnumed.123.266211

Vancouver

Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial. Journal of Nuclear Medicine. 2024;65(2):264-269. doi:10.2967/jnumed.123.266211

BibTeX
@article{Garin2024,
  author = {Garin, Etienne and Tselikas, Lambros and Guiu, Boris and Chalaye, Julia and Rolland, Yan and de Baere, Thierry and Assenat, Eric and Tacher, Vania and Palard, Xavier and Déandreis, Desirée and Mariano-Goulart, Denis and Amaddeo, Giuliana and Boudjema, Karim and Hollebecque, Antoine and Meerun, Mohamad Azhar and Regnault, Helen and Vibert, Eric and Campillo-Gimenez, Boris and Edeline, Julien},
  title = {Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {264--269},
  doi = {10.2967/jnumed.123.266211}
}
Kostenlos starten →